cell-line-engineering
(2)
Antiverse
Antiverse is a UK-based AI-driven biotech that designs functional therapeutic antibodies against targets long considered 'undruggable' - notably G-protein coupled receptors (GPCRs), ion channels, and other transmembrane proteins where conventional antibody discovery routinely fails. Its platform pairs generative AI models, trained for years on the hardest antibody targets, with a proprietary 'lab-in-the-loop' wet lab using engineered cell lines and deep sequencing, taking a target to an optimized antibody in roughly four months. Founded in 2017 and headquartered in Cardiff, Wales, the company works through pharma partnerships and licensing (e.g. Nxera Pharma) alongside its own internal pipeline and non-profit collaborations such as the Cystic Fibrosis Foundation.
Triplebar
Triplebar is an Emeryville, California biotech company that pairs a high-throughput microfluidic screening platform with AI genomic models to run evolution at hyper-speed. By packing tens of millions of picoliter microreactors onto a palm-sized chip and testing thousands per second, it generates matched genotype-phenotype datasets that let partners optimize cell lines and microbial strains far faster and cheaper than conventional lab work. The platform powers products across food (precision fermentation, cultivated meat) and biopharma (biologics, cell-engaging cancer therapies).